modified Supercritical Anti-Solvent (mSAS®) particle engineering

CrystecPharma is a global pharmaceutical technology company and crystal and particle engineering company applying its proprietary mSAS® (modified Supercritical Anti-Solvent) supercritical-fluid platform to improve the performance of medicines. The technology optimises small and large molecule therapeutics, enhancing bioavailability, stability and delivery, and is approved by regulatory authorities. The company works with the global pharmaceutical and healthcare industry and is also developing its own therapies in women's health, urology and respiratory d

Read more

AI-accelerated product developmentbiomolecule processingformulation developmentparticle size and shape engineeringscale-up and commercial GMP manufacturesolvent and impurity removalsupercritical fluid crystallisation